Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling-Reference-Cited by-同舟云学术

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

Published:2008-01-11 Issue:5b Volume:12 Page:2107-2118
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:

Author:

Chen J.,Schmitt A.,Chen B.,Rojewski M.,RuBeler V.,Fei F.,Yu Y.,Yu X.,Ringhoffer M.,von Harsdorf S.,Greiner J.,Gbtzz M.,Guillaume P.,Dbhner H.,Bunjes D.,Schmitt M.

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1582-4934.2008.00234.x/fullpdf

Reference40 articles.

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;NEngl JMed.,2001

2. Imatinib mesylate-a new oral targeted therapy;Savage;N Engl J Med.,2002

3. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene;Magnusson;Blood.,2002

4. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation;Millot;Leukemia.,2006

5. Chronic myeloid leukemia after treatment of lymphoid malignancies: Response to imatinib mesylate and favorable outcomes in three patients;Ramanarayanan;Leuk Res.,2006

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents;Dermatology and Therapy;2024-06-22

2. Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions;Experimental Hematology;2024-01

3. Viral Infections and Incidence of Reactivations in Chronic Myeloid Leukemia Patients;Oncology;2023-10-17

4. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon‐alpha;British Journal of Haematology;2023-07-22

5. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib;Cancer Immunology, Immunotherapy;2023-01-05